3.88 USD
+0.05 (+1.31%)
Overall SRTS gets a fundamental rating of 5 out of 10. We evaluated SRTS against 184 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for SRTS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, SRTS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SRTS had negative earnings in the past year.
SRTS had a positive operating cash flow in the past year.
Of the past 5 years SRTS 4 years were profitable.
SRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRTS has a better Return On Assets (-5.16%) than 66.30% of its industry peers.
Looking at the Return On Equity, with a value of -5.87%, SRTS is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| ROIC | N/A |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of SRTS has remained more or less at the same level.
SRTS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 47.95%, SRTS is in line with its industry, outperforming 41.30% of the companies in the same industry.
SRTS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.95% |
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
2. Health
2.1 Basic Checks
SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRTS has been increased compared to 1 year ago.
SRTS has about the same amout of shares outstanding than it did 5 years ago.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SRTS has an Altman-Z score of 6.73. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
SRTS has a Altman-Z score of 6.73. This is amongst the best in the industry. SRTS outperforms 82.07% of its industry peers.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.73 |
ROIC/WACCN/A
WACC8.8%
2.3 Liquidity
SRTS has a Current Ratio of 7.38. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.38, SRTS belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
A Quick Ratio of 5.27 indicates that SRTS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.27, SRTS belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
SRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -133.33%.
Measured over the past years, SRTS shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.56% on average per year.
SRTS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.80%.
The Revenue has been growing by 8.93% on average over the past years. This is quite good.
EPS 1Y (TTM)-133.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-185.71%
Revenue 1Y (TTM)-13.8%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-22.12%
3.2 Future
The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.67% on average over the next years. This is quite good.
EPS Next Y-187.55%
EPS Next 2Y-84.03%
EPS Next 3Y-29.92%
EPS Next 5Y11.64%
Revenue Next Year-21.22%
Revenue Next 2Y0.32%
Revenue Next 3Y6.2%
Revenue Next 5Y14.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRTS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 380.39, which means the current valuation is very expensive for SRTS.
Based on the Price/Forward Earnings ratio, SRTS is valued a bit cheaper than the industry average as 64.13% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.84. SRTS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 380.39 |
4.2 Price Multiples
79.89% of the companies in the same industry are more expensive than SRTS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.42 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRTS's earnings are expected to decrease with -29.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.03%
EPS Next 3Y-29.92%
5. Dividend
5.1 Amount
No dividends for SRTS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SRTS (12/22/2025, 12:42:21 PM)
3.88
+0.05 (+1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners28.64%
Inst Owner Change-23.14%
Ins Owners17.66%
Ins Owner Change1.59%
Market Cap63.75M
Revenue(TTM)35.61M
Net Income(TTM)-3.01M
Analysts82.22
Price Target7.48 (92.78%)
Short Float %3.98%
Short Ratio4.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-144.08%
Min EPS beat(2)-326.24%
Max EPS beat(2)38.08%
EPS beat(4)1
Avg EPS beat(4)-219.59%
Min EPS beat(4)-561.36%
Max EPS beat(4)38.08%
EPS beat(8)5
Avg EPS beat(8)85.83%
EPS beat(12)6
Avg EPS beat(12)12.6%
EPS beat(16)8
Avg EPS beat(16)15.03%
Revenue beat(2)1
Avg Revenue beat(2)-7.99%
Min Revenue beat(2)-22.89%
Max Revenue beat(2)6.91%
Revenue beat(4)3
Avg Revenue beat(4)3.8%
Min Revenue beat(4)-22.89%
Max Revenue beat(4)18.13%
Revenue beat(8)7
Avg Revenue beat(8)32.09%
Revenue beat(12)7
Avg Revenue beat(12)12.6%
Revenue beat(16)10
Avg Revenue beat(16)14.6%
PT rev (1m)-2.22%
PT rev (3m)-8.33%
EPS NQ rev (1m)-27.27%
EPS NQ rev (3m)-600%
EPS NY rev (1m)-4.04%
EPS NY rev (3m)-176.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.16%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)-0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 380.39 | ||
| P/S | 1.79 | ||
| P/FCF | 29.42 | ||
| P/OCF | 33.41 | ||
| P/B | 1.25 | ||
| P/tB | 1.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.19
EYN/A
EPS(NY)0.01
Fwd EY0.26%
FCF(TTM)0.13
FCFY3.4%
OCF(TTM)0.12
OCFY2.99%
SpS2.17
BVpS3.12
TBVpS3.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.95% | ||
| FCFM | 6.09% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 115.63% | ||
| Cap/Sales | 0.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 6.73 |
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)82.92%
Cap/Depr(5y)64.01%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-185.71%
EPS Next Y-187.55%
EPS Next 2Y-84.03%
EPS Next 3Y-29.92%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-13.8%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-22.12%
Revenue Next Year-21.22%
Revenue Next 2Y0.32%
Revenue Next 3Y6.2%
Revenue Next 5Y14.67%
EBIT growth 1Y-145.49%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-196.25%
EBIT Next 3Y-15.65%
EBIT Next 5Y-27.34%
FCF growth 1Y114.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.79%
OCF growth 3YN/A
OCF growth 5YN/A
SENSUS HEALTHCARE INC / SRTS FAQ
What is the ChartMill fundamental rating of SENSUS HEALTHCARE INC (SRTS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to SRTS.
Can you provide the valuation status for SENSUS HEALTHCARE INC?
ChartMill assigns a valuation rating of 2 / 10 to SENSUS HEALTHCARE INC (SRTS). This can be considered as Overvalued.
What is the profitability of SRTS stock?
SENSUS HEALTHCARE INC (SRTS) has a profitability rating of 3 / 10.
What is the expected EPS growth for SENSUS HEALTHCARE INC (SRTS) stock?
The Earnings per Share (EPS) of SENSUS HEALTHCARE INC (SRTS) is expected to decline by -187.55% in the next year.